Anagenics Limited · ASX:AN1
Anagenics — Cellmid — FY2020 Earnings Presentation
21 slides from Anagenics's earnings presentation, Aug 27, 2020
Slide 1: FY2020 Financial Results
FY2020 Financial Results 27 August 2020 ASX: CDY 1
Slide 2: Forward looking statements
Cellmid is leading innovation in anti-aging haircare globally with deep expertise in hair biology and an increasing digital and social commerce footprint in Australia, USA, Japan and China Forward looking statements This presentation contains forward-looking statements that are subject to risks and
Slide 3: Innovative Anti-Aging Hair Care Products
INNOVATIVE ANTI-AGING HAIR CARE PRODUCTS The only anti-aging haircare product range that is based on natural ingredients, clinically and scientifically validated, and effective in reducing hair loss and increasing hair growth • ‘First in class’ and ‘best in class’ clinically validated anti-aging hai
Slide 4: Agenda
AGENDA 1. FY2020 Highlights 2. Consumer Health: Segment Reporting 3. Growth Strategy: Implementation 4. Lyramid: Segment Reporting 5. Outlook 4
Slide 5: FY2020 Highlights
FY2020 HIGHLIGHTS 5
Slide 6: Resilience Through COVID-19 Disruption
RESILIENCE THROUGH COVID-19 DISRUPTION • Strong sales momentum in early FY2020: In 1H FY2020, 18 new distribution channels in Australia, USA, Japan, Europe and Asia were established and expanded, which was expected to continue accelerating sales growth in 2H FY2020. • Retail closures led to stable r
Slide 7: Consumer Health – FY2020 Highlights
CONSUMER HEALTH – FY2020 HIGHLIGHTS AUD$M FY2020 FY2019 FY2018 • Stable YOY sales growth: Consumer health revenue increased by 1% to $7.44m in FY2020 (FY2019: $7.34m). Consumer Health Revenue 7.44 7.34 5.65 Strong positive momentum in 1H FY2020 was capped in 2H due to COVID-19 business disruption. C
Slide 8: Consolidated – FY2020 Highlights
CONSOLIDATED – FY2020 HIGHLIGHTS % change AUD$M FY2020 FY2019 FY2018 • Investment in inventory and marketing: In FY2020, FY2020/FY2019 inventory increased to $2.61M (FY2019: $1.6m) and PROFIT & LOSS advertising and marketing expenses increased by $390K to reflect the expansion of distribution channe
Slide 9: Expansion of Diagnostic Assets
EXPANSION OF DIAGNOSTIC ASSETS • Supply Agreement: Cellmid signed supply, introducer and distribution agreements for a range of SARS-CoV-2 antibody and PCR tests, including the Wondfo SARS-CoV-2 antibody (Wondfo Test) test. The first commercial shipment of the Wondfo Test was received in April 2020.
Slide 10: Consumer Health: Segment Reporting
CONSUMER HEALTH: SEGMENT REPORTING 10
Slide 11: Japan
JAPAN %Δ AUD$M FY2020 FY2019 FY2018 FY2020/FY2019 FY2021 Expansion Opportunities Reported Revenue 5.61 5.93 4.23 down 5% • Export sales to China: Increasing sales of heritage brands into China through partnerships with Chinese distributors of Jo-Ju® and Lexilis®. Operating Profit 0.51 1.66 0.71 down
Slide 12: Australia
AUSTRALIA %Δ AUD$M FY2020 FY2019 FY2018 FY2020/FY2019 FY2021 Expansion Opportunities Reported Revenue 1.19 0.99 1.21 up 21% • Further collaboration with Priceline: Cellmid will continue to invest in the strategic partnership with Priceline through online education, training and customer engagement.
Slide 13: USA
USA %Δ AUD$M FY2020 FY2019 FY2018 FY2020/FY2019 FY2021 Expansion Opportunities Reported Revenue 0.63 0.42 0.2 up 51% • Impact from premium salon distributor: The agreement with Tru Beauty came into effect on 1 August 2020 and will contribute to sales growth in FY2021. Operating Loss (0.67) (0.85) (0
Slide 14: Growth Strategy: Demonstrating Track Record of Implementing Key Objectives
GROWTH STRATEGY: DEMONSTRATING TRACK RECORD OF IMPLEMENTING KEY OBJECTIVES 14
Slide 15: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM * Hired in FY2019 Raj Ghatge | Marketing Director Maria Halasz | CEO and Managing Director Brand Building, e-commerce Strategy, Business Development, Life Sciences Dr Dominic Burg | Chief Operating Officer Gary McCaw | Sales Director Data Analytics, Regulatory, Life Scien
Slide 16: Growth Strategy: Implementation
GROWTH STRATEGY: IMPLEMENTATION 1. Diversify distribution 2. Expand e-commerce 3. Expand 4. New product 5. Prepare for Strategic through own website leadership launch separation of objectives and online partnerships team businesses ✓ Started television shopping ✓ Launched updated website ✓ Appointed
Slide 17: E-Commerce Strategy Validated
E-COMMERCE STRATEGY VALIDATED • Over the past 18 months, Cellmid has actively invested in its own e-commerce infrastructure and digital marketing capabilities plus distribution partnerships with online retailers • This e-commerce growth strategy was validated in 2HY2020, enabling Cellmid to effectiv
Slide 18: Lyramid: Segment Reporting
LYRAMID: SEGMENT REPORTING 18
Slide 19: Strategic Review - Separate Lyramid Assets
STRATEGIC REVIEW - SEPARATE LYRAMID ASSETS Cellmid’s strategy is to unlock shareholder value by separating the consumer health and biotech businesses • New patents: Additional patent coverage was received for its “Improved Midkine Antibody” patent in Europe, providing further protection for its huma
Slide 20: Outlook
OUTLOOK 20
Slide 21: FY2021: Upcoming Milestones
FY2021: UPCOMING MILESTONES Increase market penetration in China through cross border e-commerce Increase market penetration into China through offline marketing taking advantage of the import permits for Jo-Ju® and Lexilis® Expansion of online sales in the US through Amazon, Dermstore, Beauty Colle